NCT05885503View on ClinicalTrials.gov

Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema

PHASE3RecruitingINTERVENTIONAL
Enrollment

316

Participants

Timeline

Start Date

June 8, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Diabetic Macular Edema
Interventions
BIOLOGICAL

RC-28E

Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 μL per dose.

BIOLOGICAL

Aflibercept

Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 μL per dose.

Trial Locations (1)

100010

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

RemeGen Co., Ltd.

INDUSTRY